Bioequivalence Study of Clopidogrel Tablets 75 mg Under Fed Conditions
NCT01512485 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 51
Last updated 2012-01-19
Summary
The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's Laboratories Ltd, clopidogrel and Bristol-Myers Squibb Company, USA Plavix®, clopidogrel 75 mg tablet under fed condition.
Conditions
- Healthy
Interventions
- DRUG
-
Clopidogrel
Clopidogrel Tablets 75 mg
Sponsors & Collaborators
-
Dr. Reddy's Laboratories Limited
lead INDUSTRY
Principal Investigators
-
Denis Audet, MD · Anapharm
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-10-31
- Primary Completion
- 2006-10-31
- Completion
- 2006-10-31
Countries
- Canada
Study Locations
More Related Trials
-
Clopidogrel Bioequivalence Study in Healthy Subjects
NCT02185534 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® 75 mg Tablet After Oral Administration to Healthy Adult Subjects Under Fasting Condition
NCT05186129 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Clopidogrel Tablets Under Fasting Conditions
NCT01630642 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects
NCT02502812 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents
NCT00947843 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacokinetic Study of Single Doses of Clopidogrel, 75 mg and 300 mg, in Healthy Subjects
NCT01129063 ·Status: COMPLETED ·Phase: PHASE1
-
Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects
NCT01129271 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects
NCT01123824 ·Status: COMPLETED ·Phase: PHASE1
-
A Bioequivalence Study Comparing Clopidogrel/Aspirin Combination Tablet With Coadministration of Clopidogrel and Aspirin
NCT01448330 ·Status: COMPLETED ·Phase: PHASE1
-
Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products
NCT02010632 ·Status: COMPLETED ·Phase: PHASE1
-
Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)
NCT02060786 ·Status: COMPLETED ·Phase: PHASE4
-
Influence of Clopidogrel on the Pharmacodynamics and Safety of Terbogrel in Healthy Male Subjects
NCT02222987 ·Status: COMPLETED ·Phase: PHASE1
-
Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI
NCT00889044 ·Status: UNKNOWN ·Phase: PHASE3
-
Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients
NCT01830491 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27
NCT01509365 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Trial to Evaluate the Influence of Genotype on the Pharmacokinetics/Pharmacodynamics of Clopidogrel
NCT01503658 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
NCT00386191 ·Status: COMPLETED ·Phase: PHASE4
-
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel
NCT00433784 ·Status: COMPLETED ·Phase: PHASE4
-
Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism
NCT00915733 ·Status: COMPLETED ·Phase: PHASE4
-
Adjunctive Cilostazol Versus High Maintenance-dose Clopidogrel According to Cytochrome 2C19 Polymorphism
NCT01012193 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540
NCT01557335 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy Volunteers
NCT01482117 ·Status: COMPLETED ·Phase: NA
-
Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination
NCT01663038 ·Status: COMPLETED ·Phase: PHASE1
-
Replication of the PLATO Antiplatelet Trial in Healthcare Claims Data
NCT04237935 ·Status: COMPLETED
-
Pharmacokinetics & Safety Study of Clopidogrel 75mg and Aspirin 100mg Coadministration
NCT01526122 ·Status: COMPLETED ·Phase: PHASE1